Bipolar disorder and schizophrenia may show 'anticipation,' or earlier age-of-onset in successive generations within a pedigree, suggesting that triplet repeat expansion mutations could play a causative role in these disorders. This genetic hypothesis can be tested using a candidate gene approach.
twin studies, there appear to be genetic components to both bipolar disorder and schizophrenia. However,
The group in Wales has now used this novel reagent to screen for possible glutamine repeat expansions in there are many aspects of the inheritance of these disorders not described by classic Mendelian genetics, bipolar disorder and schizophrenia. 9 They have not identified any expansions in the patients they have including incomplete and age-dependent penetrance, variable phenotype, and probable phenocopies. The tested. These results are discussed in the context of several limitations. For instance, detection of expansuggestion that some forms of these disorders may be characterized by anticipation (earlier age-of-onset in sions by this technique may have been limited by the patients and tissues studied. The authors, reasonably, successive generations within a pedigree) and thus be caused by an expanding triplet repeat mutation has chose to test patients with RED product expansions. However, RED can detect many other expanded triplet provided a hypothesis that could potentially explain some of these difficulties. [1] [2] [3] There is at least suggestive repeats in the genome besides those which cause disease. For instance, in a recent study of patients with evidence for anticipation in both bipolar disorder and schizophrenia, though numerous observational biases Huntington's disease 10 most of the patients had RED products most likely unrelated to the HD gene. Also, a make the delineation of anticipation difficult on purely clinical grounds. Even in myotonic dystrophy, a disrecently cloned CTG expansion, termed 18.1, is detected by the RED technique but is not associated ease with marked anticipation based on clinical observation, the anticipation controversy resolved only after with a disease. 11 As an alternative, patients might be selected for testing based on early age-of-onset or their identification of the disease gene with its expanding triplet repeat. presence in the second or third generation of a pedigree with anticipation. Because of the complexity of psychiatric genetics, linkage analysis has been much more difficult than in Another limitation relates to the expression level of polyglutamine-containing proteins. The 1C2 antibody Mendelian disorders, and no genes for psychiatric disorders have yet been discovered. The attractive feature detects many bands even in normal individuals, indicating that there are proteins containing relatively long of the anticipation hypothesis is that it is directly testable. One can look for expanded triplet repeats in DNA stretches of polyglutamine which do not cause disease. These include the TATA-binding protein as well as yet from patients with schizophrenia and bipolar disorder. Several techniques are now available to search for such uncharacterized proteins with long polyglutamine repeats. 12 Other proteins expressed at low levels might expansions. These include the ligase-chain-reactionbased 'repeat expansion detection' (RED) technique 4 be difficult to detect against this background.
However, the major limitation to the use of the 1C2 and hybridization techniques that allow both the detection and the cloning of such repeats. 5, 6 One class antibody to detect mutations in schizophrenia and bipolar disorder is the nature of the neuropathology of of triplet repeat disorders is caused by expanding CAG repeats coding for polyglutamine. 7 The development of these disorders. All of the diseases so far found to be caused by expanding CAG repeats coding for polyglutan antibody (IC2) which selectively recognizes amine are progressive neurodegenerative disorders. There is little evidence for neuronal degeneration or forms of fragile X syndrome are caused by expansion
